2006
Managing cutaneous side effects associated with erlotinib in head and neck cancer (HNC) and non-small cell lung cancer (NSCLC) patients (pts)
Oishi K, Garey J, Burke B, Herbst R, Kim E. Managing cutaneous side effects associated with erlotinib in head and neck cancer (HNC) and non-small cell lung cancer (NSCLC) patients (pts). Journal Of Clinical Oncology 2006, 24: 18538-18538. DOI: 10.1200/jco.2006.24.18_suppl.18538.Peer-Reviewed Original ResearchGrade 1 rashPartial responseGrade 2Epidermal growth factor receptorGrade 3NSCLC ptsDose modificationComplete responseTreatment algorithmTreatment responseSide effectsNon-small cell lung cancer patientsGrade 1Cell lung cancer patientsPrior chemotherapy regimenPhase II studyCutaneous side effectsLung cancer patientsGrade 4Acneiform rashChemotherapy regimenDose delaysGrowth factor receptorII studyCutaneous toxicity
2003
Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management
Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management. Clinical Lung Cancer 2003, 4: 366-369. PMID: 14599302, DOI: 10.3816/clc.2003.n.016.Peer-Reviewed Original ResearchDermatologic effectsGefitinib treatmentClinical trialsDry skinSide effectsFrequent drug-related adverse effectsDrug-related allergic reactionsRecent phase II trialDrug-related adverse effectsAdverse effectsDermatologic adverse effectsPhase II trialDermatologic side effectsCell lung cancerNumerous clinical trialsSimilar side effectsVariety of treatmentsMechanism of actionAcneiform rashTopical clindamycinAdvanced NSCLCEpidermal growth factor receptor tyrosine kinaseII trialMost patientsGefitinib therapy